52 related articles for article (PubMed ID: 36595075)
1. Prognostic Impact of Lymphocyte-to-C-Reactive Protein Ratio in Patients Who Underwent Surgical Resection for Pancreatic Cancer.
Iseda N; Iguchi T; Hirose K; Itoh S; Honboh T; Sadanaga N; Matsuura H
Am Surg; 2023 Nov; 89(11):4452-4458. PubMed ID: 35920820
[TBL] [Abstract][Full Text] [Related]
2. Importance of Progression-free Survival in Second-line Chemotherapy in Patients With Advanced or Recurrent Gastric Cancer.
Sano A; Sohda M; Hosoi N; Tateno K; Watanabe T; Uchida S; Nakazawa N; Osone K; Okada T; Shiraishi T; Sakai M; Ogawa H; Shirabe K; Saeki H
Anticancer Res; 2023 Nov; 43(11):5205-5213. PubMed ID: 37909978
[TBL] [Abstract][Full Text] [Related]
3. The clinical impacts of lymphocyte-to-C-reactive protein ratio for esophageal cancer patients who receive curative treatment.
Aoyama T; Nagasawa S; Nakazono M; Segami K; Tamagawa H; Tamagawa A; Hara K; Oshima T; Yukawa N; Masuda M; Rino Y
J Cancer Res Ther; 2023; 19(3):556-561. PubMed ID: 37470574
[TBL] [Abstract][Full Text] [Related]
4. Prognostic role of preoperative lymphocyte/C-reactive protein associated with upper gastrointestinal cancer: a meta-analysis.
Ye Y; Wu G; Yuan H; Zheng Y; Wang Y; Guo Q
Front Oncol; 2023; 13():1181649. PubMed ID: 37849797
[TBL] [Abstract][Full Text] [Related]
5. HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies.
Pous A; Notario L; Hierro C; Layos L; Bugés C
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511163
[TBL] [Abstract][Full Text] [Related]
6. Programmed death-ligand 1 (PD-L1) expression in primary gastric adenocarcinoma and matched metastases.
Liu DHW; Grabsch HI; Gloor B; Langer R; Dislich B
J Cancer Res Clin Oncol; 2023 Nov; 149(14):13345-13352. PubMed ID: 37491637
[TBL] [Abstract][Full Text] [Related]
7. Three-year survival and distribution of lymph node metastases in gastric cancer following neoadjuvant chemotherapy: results from a European randomized clinical trial.
van der Wielen N; Daams F; Rosati R; Parise P; Weitz J; Reissfelder C; Del Val ID; Loureiro C; Parada-González P; Pintos-Martínez E; Vallejo FM; Achirica CM; Sánchez-Pernaute A; Campos AR; Bonavina L; Asti ELG; Poza AA; Gilsanz C; Nilsson M; Lindblad M; Gisbertz SS; van Berge Henegouwen MI; Romario UF; De Pascale S; Akhtar K; Cuesta MA; van der Peet DL; Straatman J
Surg Endosc; 2023 Sep; 37(9):7317-7324. PubMed ID: 37468751
[TBL] [Abstract][Full Text] [Related]
8. INTRAPERITONEAL CHEMOTHERAPY FOR GASTRIC CANCER WITH PERITONEAL CARCINOMATOSIS: STUDY PROTOCOL OF A PHASE II TRIAL.
Ramos MFKP; Pereira MA; Charruf AZ; Victor CR; Gregorio JVAM; Alban LBV; Moniz CMV; Zilberstein B; Mello ES; Hoff PMG; Ribeiro Junior U; Dias AR
Arq Bras Cir Dig; 2023; 36():e1744. PubMed ID: 37466566
[TBL] [Abstract][Full Text] [Related]
9. Lymphocyte-to-C Reactive Protein Ratio is an Independent Predictor of Survival Benefits for Hepatocellular Carcinoma Patients Receiving Radiotherapy.
Shi Z; Zhu S; Jin Y; Qi L; Zhou M; Zhou Z; Zhang J; Liu B; Shen J
J Hepatocell Carcinoma; 2024; 11():305-316. PubMed ID: 38348098
[TBL] [Abstract][Full Text] [Related]
10. Lymphocyte-to-C-reactive protein ratio and score are clinically feasible nutrition-inflammation markers of outcome in patients with gastric cancer.
Okugawa Y; Toiyama Y; Yamamoto A; Shigemori T; Ichikawa T; Yin C; Suzuki A; Fujikawa H; Yasuda H; Hiro J; Yoshiyama S; Ohi M; Araki T; McMillan DC; Kusunoki M
Clin Nutr; 2020 Apr; 39(4):1209-1217. PubMed ID: 31155370
[TBL] [Abstract][Full Text] [Related]
11. Could lymphocyte to C-reactive protein ratio predict the prognosis in patients with gastric cancer?
Angin YS; Yildirim M; Dasiran F; Okan I
ANZ J Surg; 2021 Jul; 91(7-8):1521-1527. PubMed ID: 33956378
[TBL] [Abstract][Full Text] [Related]
12. The prognostic impact of the lymphocyte-to-C-reactive protein ratio in patients with unresectable or recurrent advanced gastric cancer treated with first- and second-line treatment.
Matsunaga T; Saito H; Fukumoto Y; Kuroda H; Taniguchi K; Takahashi S; Osaki T; Iwamoto A; Fukuda K; Shimizu S; Shishido Y; Miyatani K; Fujiwara Y
Surg Today; 2023 Aug; 53(8):940-948. PubMed ID: 36595075
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of lymphocyte-to-C-reactive protein ratio in patients with gastric cancer after surgery: a multicentre study.
Cheng CB; Zhang QX; Zhuang LP; Sun JW
Jpn J Clin Oncol; 2020 Sep; 50(10):1141-1149. PubMed ID: 32564084
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of lymphocyte to C-reactive protein ratio in predicting survival and postoperative complication for esophago-gastric junction cancer.
Tsujiura M; Yamamoto A; Imaoka H; Shimura T; Kitajima T; Morimoto Y; Kawamura M; Yasuda H; Okita Y; Yokoe T; Okugawa Y; Ohi M; Toiyama Y
Surg Oncol; 2022 Sep; 44():101842. PubMed ID: 36081281
[TBL] [Abstract][Full Text] [Related]
15. Neutrophil-to-Lymphocyte Ratio as a Prognostic Indicator in Patients With Unresectable Gastric Cancer.
Murakami Y; Saito H; Shimizu S; Kono Y; Shishido Y; Miyatani K; Matsunaga T; Fukumoto Y; Fujiwara Y
Anticancer Res; 2019 May; 39(5):2583-2589. PubMed ID: 31092456
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
